丽珠医药集团股份有限公司 2013 年第一季度报告全文
Livzon Pharmaceutical Group Inc.
2013 First Quarterly Report
Announcement No.: 2013-20
April 2013
丽珠医药集团股份有限公司 2013 年第一季度报告全文
Section I Important Notice
The Board of Directors (BOD), Board of Supervisors (BOS), directors, supervisors and senior executives
hereby guarantee that the data in this quarterly report contain no false representation, misleading
statements and serious omissions, and shall be severally and jointly liable for the contents.
Mr. Zhu Baoguo, Chairman of the company, Mr. An Ning, the principal in charge of accounting, and Ms.
Si Yanxia, the principal of the Accounting Department hereby declare: We guarantee the authenticity and
completeness of the financial statements in this quarterly report.
All directors were personally present in the meeting of Board of Director examining this quarterly report.
This report is made both in Chinese and English; in case there is any contraction between the Chinese
and English versions, the Chinese version shall prevail.
丽珠医药集团股份有限公司 2013 年第一季度报告全文
Section II Main Financial Data and shareholder changes
I. Main financial data
Whether there are retrospective adjustments or descriptions of financial data in previous years in this report period.
□ Yes √ No
Increase or
decrease
January to March January to March
compared with
2013
same period of
previous year (%)
Total profit(RMB Yuan) 1,055,640,495.32 892,862,698.79 18.23%
Net profit attributable to the shareholders of listed
146,739,417.67 117,291,231.12 25.11%
companies (RMB Yuan)
Net profit attributable to the shareholders of listed
companies after deduction of non-recurring profit and 138,769,476.59 109,667,397.10 26.54%
loss(RMB Yuan)
Net cash flows from operating activities (RMB Yuan) 48,651,126.55 133,979,956.38 -63.69%
Basic profit per share (RMB Yuan per share) 0.50 0.40 25.00%
Diluted profit per share (RMB Yuan per share) 0.50 0.40 25.00%
Up 0.72 percenta
Weighted average yield rate of net assets (%) 4.76% 4.04%
ge points
Increase or
decrease
March 31, 2013 March 31, 2012 compared with
end of previous
year (%)
Total assets (RMB Yuan) 5,959,089,293.50 5,633,753,961.14 5.77%
Net asset per share attributable to the shareholders of
3,154,805,304.99 3,008,015,808.63 4.88%
listed companies(RMB Yuan)
Non-recurring profit and loss items and amounts
√ Applicable □ Inapplicable
Unit: RMB Yuan
Amount from year
Non-recurring profit and loss items beginning to end of Note (if applicable)
report period
Profit and loss in disposal of non-current assets 4,747.38
Governmental allowance accrued to the current profit and loss, 6,082,200.68 All governmental
丽珠医药集团股份有限公司 2013 年第一季度报告全文
except those that are closely related to the normal operation allowances received by
businesses of company, comply with the national policies, and are the Company
continuously granted based on the certain standard quota or certain
quantity
Except the effective hedge business related to the normal operation
business of the company, the profit and loss in the changes of fair
values caused by the holding of tradable financial assets and tradable Returns from securitie
1,861,677.94
financial liabilities as well as the investment returns in disposal of s investment
tradable financial assets, tradable financial liabilities and saleable
financial assets
Other net non-operating income and payment except the above items 1,079,528.10
Subtotal 9,018,659.34
Minus: Effect of the minority of shareholders’ equities 955.97
Effect of income tax 1,049,674.23
Total 7,969,941.08 -
II. Total quantity of shareholders and shareholding particulars of top ten
shareholders at the end of report period
Unit: share
Total quantity of shareholders at the end of
17,543(including 6,045 B-share holders)
report period
Shares held by top ten shareholders
Total quantity Shares for
Shareholdi Total
Shareholder of shares with the
Shareholder name (full name) ng shareholding
nature trading mortgage or
percentage quantity
restriction freezing
Domestic
Joincare Pharmaceutical Group
non-state-owne 26.21% 77,510,167
Industry Co., Ltd
d legal person
Foreign legal
Tiancheng Industry Co., Ltd 17.13% 50,660,052 50,660,052
person
Foreign legal
First Shanghai Securities Co., Ltd 3.66% 10,838,198 10,106,560
person
Foreign legal
GAOLING FUND,L.P. 3.64% 10,767,777 10,767,777
person
Bank of China – Harvest Study Fine
Stock-type Securities Investment Others 2.47% 7,312,201
Fund
Industrial and Commercial Bank of
China- Harvest Strategic Growth Others 2.39% 7,071,617
Mixed Securities Investment Fund
Agricultural Bank of China – Penghua
power growth mixed securities Others 2.33% 6,900,000
investment funds
Industrial and Commercial Bank of Others 2.10% 6,219,462
丽珠医药集团股份有限公司 2013 年第一季度报告全文
China- E-fund Value Growth Mix
Securities Investment Fund
Guangzhou Begol Trading State-owned Mortgaged
2.05% 6,059,428 6,059,428
Corporation legal person and frozen
Domestic
Shenzhen Haibin Pharmaceutical Co.,
non-state-owne 1.99% 5,892,943
Ltd
d legal person
Shareholding particulars of top ten shareholders without trading restriction
Quantity of
Shareholder name shares without Share type Quantity
trading restriction
RMB common
Joincare Pharmaceutical Group Industry Co., Ltd 77,510,167 77,510,167
share
Bank of China – Harvest Study Fine Stock-type Securities RMB common
7,312,201 7,312,201
Investment Fund share
Industrial and Commercial Bank of China- Harvest Strategic RMB common
7,071,617 7,071,617
Growth Mixed Securities Investment Fund share
Agricultural Bank of China – Penghua power growth mixed RMB common
6,900,000 6,900,000
securities investment funds share
Industrial and Commercial Bank of China- E-fund Value Growth RMB common
6,219,462 6,219,462
Mix Securities Investment Fund share
RMB common
Shenzhen Haibin Pharmaceutical Co., Ltd 5,892,943 5,892,943
share
Agricultural Bank of China- Greatwall Anxin Return Mixed RMB common
5,500,000 5,500,000
Securities Investment Fund share
Agricultural Bank of China- Invesco Greatwall Domestic Needs RMB common
5,047,614 5,047,614
Growth No. 2 Stock-type Securities Investment Fund share
Bank of Communications – Greatwall Jiufu Core Growth RMB common
3,950,000 3,950,000
Stock-type Securities Investment Fund（LOF） share
Agricultural Bank of China- Invesco Greatwall Domestic Needs RMB common
3,390,237 3,390,237
Growth Open Securities Investment Fund share
①On January 2, 2004, Joincare Pharmaceutical Group Industry Co., Ltd (hereinafter called as “Joincare”)
and Guangzhou Begol Trading Corporation (hereinafter called as “Begol”) signed the Agreement on Equity
Transfer and Custody and the Agreement on Equity Mortgage, in which Guangzhou Begol Trading
Corporation directly transferred, custodized and mortgaged 6,059,428 domestic legal person shares of our
company to Joincare;②Tiancheng Industry Co., Ltd and Shenzhen Haibin Pharmaceutical Co., Ltd are the
Descripti
subcompanies directly or indirectly held 100% by Joincare;③Industrial and Commercial Bank of China-
on of
Harvest Strategic Growth Mixed Securities Investment Fund and Bank of China – Harvest Study Fine
concerted
Stock-type Securities Investment Fund belong to Harvest Fund Management Co., Ltd. ④Agricultural Bank of
action of
China- Greatwall Anxin Return Mixed Securities Investment Fund and Bank of Communications – Greatwall
above
Jiufu Core Growth Stock-type Securities Investment Fund (LOF) belongs to Greatwall Fund Management
sharehold
Co., Ltd; ⑤ Agricultural Bank of China- Invesco Greatwall Domestic Needs Growth No. 2 Stock-type
ers:
Securities Investment Fund and Agricultural Bank of China- Invesco Greatwall Domestic Needs Growth
Open Securities Investment Fund belongs to Invesco Great Wall Fund Management Company Limited; ⑥
The Company does not know whether there are any relations between the above shareholders or whether
they belong to the persons acting in concert stated in the Management Measures about Takeover of Listed
Companies.
Note: In accordance with the commitments separately made by Tiancheng Industry Co., Ltd, GAOLING FUND,L.P. and
SUNRISE PALACE LIMITED (First Shanghai Securities Co., Ltd holds 10,106,560 B-shares of the company on
behalf of it) at the time of implementing the transfer from B share to H share, by the end of this report period,
the shares has the trading restriction.
丽珠医药集团股份有限公司 2013 年第一季度报告全文
Section III Major Events
I. Particulars and reasons for key changes of main accounting statement items and
financial indexes during the report period
√ Applicable □ Inapplicable
1. Huge changes of balance sheet items and reasons
Item Amount at the
Amount at the
beginning of Increase or
end of period Reasons for changes
period (RMB decrease
(RMB Yuan)
Yuan)
Tradable financial 13,881,715.22 59,319,616.94 -76.60% During the report period, the company sold
assets the stocks.
363,355,912.72 207,180,789.68 75.38% The advance payment of equipment
Advance payment increases.
Rewards paid to The company pays the double salaries and
52,035,765.80 74,462,512.02 -30.12%
the staffs performance rewards to staffs.
Interests payable 14,493,409.73 10,454,004.86 38.64% The withdrawn loan interests increase.
150,700,000.00 700,000.00 21428.57% During the report period, the bank loans
Long-term loans increase by RMB 150 million Yuan.
2. Huge changes of profit statement items and reasons for such changes
Item Amount in this Amount in Change Reasons for changes
period (RMB previous rate
Yuan) period (RMB
Yuan)
During the report period, the company reduced
Loss of asset
3,185,704.22 5,836,757.42 -45.42% the bad debt reserve and depreciation loss of
depreciation
inventory.
Profits from the
changes of fair 1,006,067.22 4,971,946.09 -79.77% During the report period, the company reduced
values the securities investment.
During the report period, the company sold the
Investment returns 2,162,744.23 347,088.76 523.11%
tradable financial assets.
Non-operating During the report period, the governmental
7,291,019.38 2,612,890.25 179.04%
income allowance incomes increased.
丽珠医药集团股份有限公司
